Nicox

Nicox Liabilities

The The Liabilities of Nicox (ALCOX.PA) as of Nov 13, 2026 is 4.35 M EUR. In the previous year, The Liabilities was 21.01 M EUR — a change of -79.28% (lower).

Liabilities

4.35 MEUR

YoY

-79.28%

Last updated:

In 2025, Nicox's total liabilities amounted to 4.35 M EUR, a -79.28% difference from the 21.01 M EUR total liabilities in the previous year.

The Nicox Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2018
24.94 M EUR
Jan 1, 2019
15.45 M EUR
Jan 1, 2020
41.43 M EUR
Jan 1, 2021
39.06 M EUR
Jan 1, 2022
40.73 M EUR
Jan 1, 2023
31.57 M EUR
Jan 1, 2024
21.01 M EUR
Jan 1, 2025
4.35 M EUR
The Nicox Liabilities history
YEARLiabilitiesYoY
4.35 MEUR-79.28%
21.01 MEUR-33.45%
31.57 MEUR-22.50%
40.73 MEUR+4.29%
39.06 MEUR-5.73%
41.43 MEUR+168.25%
15.45 MEUR-38.06%
24.94 MEUR+3.74%
24.04 MEUR-45.62%
44.20 MEUR-28.73%
62.02 MEUR+15.36%
53.76 MEUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Nicox Stock analysis

What does Nicox do? Nicox SA is a French pharmaceutical company specializing in the development and commercialization of innovative therapy systems for eye diseases. It was founded in 1996 as a spin-off of Nestlé's research activities in the field of ophthalmology. The company's business model is based on the development of drugs based on nitric oxide (NO), a gaseous molecule that plays an important role in regulating blood flow and inflammation processes in the human body. Nicox SA's technology allows for the targeted release of NO donors in specific areas of the eye to reduce disease-related inflammation and damage. This provides a promising alternative to conventional therapies for a range of eye diseases. Nicox SA is divided into three business areas: Ophthalmology, Diagnostics, and Contracts. In the Ophthalmology segment, the company focuses on the development of drugs for the treatment of glaucoma, dry eye, and other eye diseases. Important products in this area include Vyzulta, a combination of an NO donor and a glaucoma drug, as well as NCX 470, an NO donor for the treatment of glaucoma. In addition, the company is working on the development of NCX 4251, an NO donor for the treatment of blepharitis, an inflammation of the eyelids. In the Diagnostics segment, Nicox SA offers innovative diagnostic tests for ophthalmology based on tear fluid analysis. These tests enable ophthalmologists to diagnose and monitor certain eye diseases more quickly and accurately. Key products in this area include AdenoPlus, a rapid test for diagnosing adenovirus conjunctivitis, and ClearSight, a test for monitoring glaucoma patients. The Contracts segment offers customized clinical research services for customers in the pharmaceutical industry. This segment is an important part of Nicox SA's strategy to generate additional revenue and finance the development of new therapies. Overall, Nicox SA has a strong pipeline of new therapies and diagnostic tests that allow the company to consolidate its position as a leading provider of eye medications. The company works closely with its industry and academic research partners to develop and bring innovative therapies to the market. In summary, Nicox SA is an innovative and rapidly growing company focusing on the development and commercialization of therapies for eye diseases. The company has a strong pipeline of new products and services and collaborates closely with its partners to strengthen its position in the industry. Nicox is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Nicox's Liabilities

Nicox's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Nicox's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Nicox's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Nicox's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Nicox’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Nicox stock

The Liabilities of Nicox is 4.35 M EUR in 2025.

The Liabilities of Nicox changed from 21.01 M EUR to 4.35 M EUR, representing a -79.28% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Nicox since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Nicox historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Nicox

All Key Metrics — Nicox